In This Article:
-
Research and Development Expenses: $16.4 million for Q3 2024, down from $28.4 million in Q3 2023.
-
General and Administrative Expenses: $5.9 million for Q3 2024, down from $6.6 million in Q3 2023.
-
Net Loss: $10.6 million for Q3 2024, compared to $33.3 million in Q3 2023.
-
Net Cash Used in Operating Activities: $55.2 million for the nine months ended September 30, 2024, compared to $74.1 million for the same period in 2023.
-
Cash and Cash Equivalents: $56.5 million as of September 30, 2024, compared to $111.5 million as of December 31, 2023.
-
Collaboration Revenue: $11 million recognized in Q3 2024 from a license agreement with Context Therapeutics.
Release Date: November 07, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
BioAtla Inc (NASDAQ:BCAB) reported promising clinical trial results for its drug candidate, Tab war 2 80 C Zy A THEIN, showing a total of 11 responses out of 29 evaluable patients with refractory head and neck cancer.
-
The drug candidate received fast track designation from the FDA, highlighting its potential in addressing unmet medical needs.
-
BioAtla Inc (NASDAQ:BCAB) observed a median overall survival of approximately nine months in heavily pretreated head and neck cancer patients, which is competitive compared to current standard treatments.
-
The company received supportive feedback from the FDA for its proposed pivotal trial design, potentially leading to accelerated marketing authorization.
-
BioAtla Inc (NASDAQ:BCAB) reported a significant decrease in research and development expenses, reflecting efficient prioritization of clinical programs and completion of preclinical development for certain assets.
Negative Points
-
BioAtla Inc (NASDAQ:BCAB) reported a net loss of $10.6 million for the quarter, despite recognizing $11 million in collaboration revenue.
-
The company's cash and cash equivalents decreased significantly from $111.5 million at the end of 2023 to $56.5 million as of September 30, 2024.
-
There is uncertainty regarding the sufficiency of cash to fund operations beyond early 2026, despite current projections.
-
The company is still in the process of determining the most efficient path for a future pivotal trial for its cab actual A DC asset MBOM, indicating potential delays.
-
BioAtla Inc (NASDAQ:BCAB) is engaged in ongoing discussions for collaborations, which may impact timelines and resource allocation for its phase two assets.
Q & A Highlights
Q: Can you clarify if the focus for your pivotal trial remains on first-line BRAF mutated melanoma, and what are the patient enrollment criteria? A: We initially identified BRAF mutated melanoma patients as a focus due to their unique benefit from CTLA-4 blockade. However, we have expanded our focus to include all first-line unresectable and metastatic melanoma patients. Our data shows tumor reductions in all eight patients treated, including those with BRAF mutations, supporting a broader patient population for the pivotal trial.